The evaluation of a novel digital immunochromatographic assay with silver amplification to detect SARS-CoV-2 - Kurihara, Yoko; Kiyasu, Yoshihiko; Akashi, Yusaku; Takeuchi, Yuto; Narahara, Kenji; Mori, Sunao; Takeshige, Tomonori; Notake, Shigeyuki; Ueda, Atsuo; Nakamura, Koji; Ishikawa, Hiroichi; Suzuki, Hiromichi (medRxiv, 2021)
Introduction Rapid antigen tests are convenient for diagnosing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); however, they have lower sensitivities than nucleic acid amplification tests. In this study, we evaluated the diagnostic performance of Quick Chaser® Auto SARS-CoV-2, a novel digital immunochromatographic assay that is expected to have higher sensitivity than conventional antigen tests.Methods A prospective observational study was conducted between February 8 and March 24, 2021. We simultaneously obtained two nasopharyngeal samples, one for evaluation with the QuickChaser® Auto SARS-CoV-2 antigen test and the other for assessment with reverse transcription PCR (RT-PCR), considered the gold-standard reference test. The limit of detection (LOD) of the new antigen test was compared with those of four other commercially available rapid antigen tests.Results A total of 1401 samples were analyzed. SARS-CoV-2 was detected by reference RT-PCR in 83 (5.9%) samples, of which 36 (43.4%) were collected from symptomatic patients. The sensitivity, specificity, positive predictive value, and negative predictive value were 74.7% (95% confidence interval (CI): 64.0–83.6%), 99.8% (95% CI: 99.5–100%), 96.9% (95% CI: 89.2–99.6%), and 98.4% (95% CI: 97.6–99.0%), respectively. When limited to samples with a cycle threshold (Ct) <30 or those from symptomatic patients, the sensitivity increased to 98.3% and 88.9%, respectively. The QuickChaser® Auto SARS-CoV-2 detected 34–120 copies/test, which indicated greater sensitivity than the other rapid antigen tests.Conclusions QuickChaser® Auto SARS-CoV-2 showed sufficient sensitivity and specificity in clinical samples of symptomatic patients. The sensitivity was comparable to RT-PCR in samples with Ct<30.Competing Interest StatementMizuho Medy provided fees for research expenses and provided the Quick Chaser Auto SARS-CoV-2 without charge. Kenji Narahara, Sunao Mori, and Tomonori Takeshige are employed by Mizuho Medy, the developer of the Quick Chaser Auto SARS-CoV-2. Hiromichi Suzuki received consultation fee from Mizuho Medy, and Fujifilm.Funding StatementMizuho Medy provided fees for research expenses and provided the Quick Chaser Auto SARS-CoV-2 without charge. Kenji Narahara, Sunao Mori, and Tomonori Takeshige are employed by Mizuho Medy, the developer of the Quick Chaser Auto SARS-CoV-2. Hiromichi Suzuki received consultation fee from Mizuho Medy, and Fujifilm.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the ethics committee of Tsukuba Medical Center Hospital (approval number: 2020-071).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available from the corresponding author, Y.K., upon reasonable request.